MCID: PRG002
MIFTS: 40

Progesterone-Receptor Positive Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Progesterone-Receptor Positive Breast Cancer

MalaCards integrated aliases for Progesterone-Receptor Positive Breast Cancer:

Name: Progesterone-Receptor Positive Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060077

Summaries for Progesterone-Receptor Positive Breast Cancer

MalaCards based summary : Progesterone-Receptor Positive Breast Cancer is related to breast cancer and vulvar syringoma. An important gene associated with Progesterone-Receptor Positive Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Bevacizumab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Progesterone-Receptor Positive Breast Cancer

Diseases in the Progesterone-Receptor Positive Breast Cancer family:

Progesterone-Receptor Negative Breast Cancer

Diseases related to Progesterone-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 132)
# Related Disease Score Top Affiliating Genes
1 breast cancer 28.7 CYP19A1 ERBB2 ESR1 ESR2 PGR
2 vulvar syringoma 10.2 ESR1 PGR
3 vestibular gland benign neoplasm 10.2 ESR1 PGR
4 lung leiomyoma 10.2 ESR1 PGR
5 bartholin's gland adenoma 10.2 ESR1 PGR
6 vulvar benign neoplasm 10.2 ESR1 PGR
7 trigonitis 10.2 ESR1 PGR
8 vulvar leiomyoma 10.2 ESR1 PGR
9 predominantly cortical thymoma 10.2 ESR1 PGR
10 cribriform carcinoma 10.2 ESR1 PGR
11 bartholin's gland benign neoplasm 10.2 ESR1 PGR
12 endometrial squamous cell carcinoma 10.2 ESR1 PGR
13 gastric signet ring cell adenocarcinoma 10.2 ESR1 PGR
14 benign metastasizing leiomyoma 10.2 CYP19A1 PGR
15 endometrial mucinous adenocarcinoma 10.2 ESR1 PGR
16 adenoid basal cell carcinoma 10.2 ESR1 PGR
17 deep angioma 10.2 ESR1 PGR
18 cervical carcinosarcoma 10.2 ESR1 PGR
19 synchronous bilateral breast carcinoma 10.2 ESR1 PGR
20 intramuscular hemangioma 10.2 ESR1 PGR
21 glycogen-rich clear cell breast carcinoma 10.2 ESR1 PGR
22 retinitis pigmentosa 47 10.2 ESR1 PGR
23 adenomyosis 10.2 ESR1 PGR
24 retinitis pigmentosa 20 10.2 ESR1 PGR
25 endometrial stromal nodule 10.2 CYP19A1 PGR
26 adenosarcoma 10.2 ESR1 PGR
27 cervical clear cell adenocarcinoma 10.2 ESR1 PGR
28 scirrhous adenocarcinoma 10.2 ERBB2 PGR
29 breast apocrine carcinoma 10.2 ERBB2 PGR
30 reproductive organ benign neoplasm 10.2 ESR1 PGR
31 uterine benign neoplasm 10.1 ESR1 PGR
32 peritoneal mesothelioma 10.1 ESR1 PGR
33 intracystic papillary adenoma 10.1 ERBB2 PGR
34 smooth muscle tumor 10.1 ESR1 PGR
35 progesterone-receptor negative breast cancer 10.1 ERBB2 PGR
36 pancreatic mucinous cystadenoma 10.1 ESR1 PGR
37 endometritis 10.1 ESR1 PGR
38 breast squamous cell carcinoma 10.1 ERBB2 PGR
39 endometrial disease 10.1 CYP19A1 ESR1
40 estrogen resistance 10.1 CYP19A1 ESR1
41 aromatase deficiency 10.1 CYP19A1 ESR1
42 microglandular adenosis 10.1 ERBB2 PGR
43 comedo carcinoma 10.1 ERBB2 ESR1
44 angiomyolipoma 10.1 ESR1 PGR
45 breast secretory carcinoma 10.1 ERBB2 PGR
46 sex cord-gonadal stromal tumor 10.1 CYP19A1 PGR
47 leydig cell tumor 10.1 CYP19A1 ESR1
48 uterine sarcoma 10.1 CYP19A1 ESR1
49 primary peritoneal carcinoma 10.1 ERBB2 PGR
50 leiomyomatosis 10.0 ESR1 PGR

Graphical network of the top 20 diseases related to Progesterone-Receptor Positive Breast Cancer:



Diseases related to Progesterone-Receptor Positive Breast Cancer

Symptoms & Phenotypes for Progesterone-Receptor Positive Breast Cancer

MGI Mouse Phenotypes related to Progesterone-Receptor Positive Breast Cancer:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 ESR2 ERBB2 PGR ESR1 CYP19A1
2 cardiovascular system MP:0005385 9.89 ESR2 ERBB2 PGR ESR1 CYP19A1
3 cellular MP:0005384 9.88 ESR2 ERBB2 ESR1 CYP19A1 PGR
4 endocrine/exocrine gland MP:0005379 9.83 ERBB2 PGR ESR1 CYP19A1 ESR2
5 integument MP:0010771 9.8 PGR ESR1 CYP19A1 ESR2 ERBB2
6 digestive/alimentary MP:0005381 9.76 ESR2 ERBB2 ESR1 CYP19A1
7 muscle MP:0005369 9.72 PGR ESR1 CYP19A1 ESR2 ERBB2
8 limbs/digits/tail MP:0005371 9.67 ESR2 ERBB2 PGR ESR1
9 neoplasm MP:0002006 9.56 ERBB2 PGR ESR1 ESR2
10 normal MP:0002873 9.55 ERBB2 PGR ESR1 CYP19A1 ESR2
11 reproductive system MP:0005389 9.35 ERBB2 PGR ESR1 CYP19A1 ESR2
12 skeleton MP:0005390 9.02 ERBB2 PGR ESR1 CYP19A1 ESR2

Drugs & Therapeutics for Progesterone-Receptor Positive Breast Cancer

Drugs for Progesterone-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Epirubicin Approved Phase 3 56420-45-2 41867
4
Fluorouracil Approved Phase 3 51-21-8 3385
5
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
6
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
7
Exemestane Approved, Investigational Phase 3,Phase 2 107868-30-4 60198
8
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1 112809-51-5 3902
9
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
10
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2 50-28-2 5757
11
Fulvestrant Approved, Investigational Phase 3,Phase 2 129453-61-8 17756771 104741
12
Zoledronic acid Approved Phase 3,Phase 2 118072-93-8 68740
13
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
14
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
15
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
16
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
17
Toremifene Approved, Investigational Phase 2, Phase 3 89778-26-7 3005573
18
Everolimus Approved Phase 3,Phase 2 159351-69-6 6442177
19
Goserelin Approved Phase 3,Phase 2 65807-02-5 5311128 47725
20
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
21
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
22
Sirolimus Approved, Investigational Phase 3,Phase 2 53123-88-9 46835353 6436030 5284616
23
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
24
Norepinephrine Approved Phase 3 51-41-2 439260
25
Methyltestosterone Approved Phase 3 58-18-4 6010
26
Testosterone Approved, Investigational Phase 3 58-22-0 6013
27
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
28
Metformin Approved Phase 3 657-24-9 4091 14219
29
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
31
Docetaxel Approved May 1996, Investigational Phase 3 114977-28-5 148124 9877265
32
Doxil Approved June 1999 Phase 3,Phase 2 31703
33 Alkylating Agents Phase 3,Phase 2
34 Angiogenesis Inhibitors Phase 3,Phase 2
35 Angiogenesis Modulating Agents Phase 3,Phase 2
36 Anti-Bacterial Agents Phase 3,Phase 2
37 Antibiotics, Antitubercular Phase 3,Phase 2
38 Antimetabolites Phase 3,Phase 2
39 Antimetabolites, Antineoplastic Phase 3,Phase 2
40 Antirheumatic Agents Phase 3,Phase 2
41 Estrogens Phase 3,Phase 2,Phase 1
42 Hormone Antagonists Phase 3,Phase 2,Phase 1
43 Hormones Phase 3,Phase 2,Phase 1
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
45 Immunosuppressive Agents Phase 3,Phase 2
46 Progestins Phase 3,Phase 1,Phase 2
47 Topoisomerase Inhibitors Phase 3,Phase 2
48 Anticoagulants Phase 3,Phase 2
49 Antineoplastic Agents, Hormonal Phase 3,Phase 2
50 Aromatase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 56)

# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
2 Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00893061 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
3 Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy Completed NCT00050011 Phase 3 Zoledronic Acid;Letrozole
4 S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Completed NCT01385137 Phase 3
5 Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients Recruiting NCT02132000 Phase 2, Phase 3 toremifene or tamoxifen
6 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Recruiting NCT01674140 Phase 3 anastrozole;everolimus;exemestane;goserelin acetate;letrozole;leuprolide acetate;tamoxifen citrate
7 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066703 Phase 3 exemestane;tamoxifen;triptorelin
8 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Active, not recruiting NCT01598298 Phase 3 duloxetine hydrochloride
9 Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment Active, not recruiting NCT01573442 Phase 3 testosterone
10 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
11 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
12 A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Active, not recruiting NCT01101438 Phase 3 metformin hydrochloride
13 Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery Active, not recruiting NCT00541086 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
14 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Active, not recruiting NCT00433589 Phase 3 anthracycline-based;docetaxel and capecitabine
15 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
16 S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Suspended NCT02137837 Phase 3 Fulvestrant;Anastrozole;Everolimus;Placebo - Anastrozole;Placebo - Everolimus
17 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Unknown status NCT01124695 Phase 2 tamoxifen citrate
18 Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer Unknown status NCT00871858 Phase 2 anastrozole;fulvestrant
19 Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer Unknown status NCT00687648 Phase 2 anastrozole;cyclophosphamide;exemestane;letrozole;methotrexate;prednisolone
20 Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer Completed NCT00057941 Phase 2 anastrozole;gefitinib;fulvestrant
21 F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer Completed NCT00602043 Phase 2
22 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2 letrozole;zoledronic acid
23 Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
24 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
25 Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy Completed NCT01160718 Phase 2 fulvestrant;selumetinib
26 Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer Completed NCT01105312 Phase 1, Phase 2 letrozole;panobinostat
27 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
28 Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer Completed NCT00755885 Phase 1, Phase 2 abiraterone acetate
29 Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus Recruiting NCT02015559 Phase 2 mucoadhesive oral wound rinse
30 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Recruiting NCT01037790 Phase 2 PD-0332991
31 Phase II Study of Everolimus Beyond Progression Active, not recruiting NCT02269670 Phase 2 everolimus;anastrozole;letrozole;tamoxifen citrate;fulvestrant;megestrol acetate
32 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer Active, not recruiting NCT01463072 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
33 Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors Active, not recruiting NCT01831076 Phase 2 Exemestane
34 Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer Terminated NCT00674557 Phase 2 SOD1 inhibitor ATN-224;exemestane
35 Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer Terminated NCT00194792 Phase 2 exemestane;triptorelin pamoate;capecitabine;methotrexate;vinorelbine tartrate;paclitaxel
36 Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain Terminated NCT00892268 Phase 2
37 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
38 Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer Withdrawn NCT00080613 Phase 2 exemestane
39 Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer Withdrawn NCT01013506 Phase 2 IGF-1R inhibitor OSI-906;erlotinib hydrochloride;goserelin;letrozole
40 Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer Withdrawn NCT01100489 Phase 2
41 BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer Active, not recruiting NCT01791478 Phase 1 PI3K inhibitor BYL719;letrozole
42 RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer Terminated NCT01208441 Phase 1 letrozole;gamma-secretase/Notch signalling pathway inhibitor RO4929097
43 Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17 Unknown status NCT00897065
44 Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer Completed NCT00755313 aromatase inhibition therapy;carboplatin;cyclophosphamide;docetaxel;doxorubicin hydrochloride
45 Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer Completed NCT00115505
46 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases Completed NCT00072293
47 A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Recruiting NCT01824836 anastrozole
48 Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer Recruiting NCT02186470
49 Assessment of Candidate Protein Expression in Breast Cancer Specimens Recruiting NCT00918892
50 Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia Recruiting NCT02954471

Search NIH Clinical Center for Progesterone-Receptor Positive Breast Cancer

Genetic Tests for Progesterone-Receptor Positive Breast Cancer

Anatomical Context for Progesterone-Receptor Positive Breast Cancer

MalaCards organs/tissues related to Progesterone-Receptor Positive Breast Cancer:

38
Breast, Bone, Lymph Node, Testes, Kidney, Brain, Endothelial

Publications for Progesterone-Receptor Positive Breast Cancer

Articles related to Progesterone-Receptor Positive Breast Cancer:

(show all 19)
# Title Authors Year
1
Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint. ( 28831439 )
2017
2
Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. ( 28251385 )
2017
3
Racial disparity in vitamin D status may explain racial disparity in survival from estrogen and progesterone receptor-positive breast cancer. ( 28396965 )
2017
4
Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer. ( 26363528 )
2015
5
Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. ( 26161666 )
2015
6
Clinical significance of SPRR1A expression in progesterone receptor-positive breast cancer. ( 25424702 )
2015
7
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. ( 23788750 )
2013
8
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. ( 23971947 )
2013
9
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. ( 23579222 )
2013
10
Progesterone and levonorgestrel regulate expression of 17I^HSD-enzymes in progesterone receptor positive breast cancer cell line T47D. ( 22564730 )
2012
11
A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. ( 22548922 )
2012
12
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. ( 20705559 )
2010
13
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. ( 19130322 )
2009
14
Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? ( 19703124 )
2009
15
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. ( 18302747 )
2008
16
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. ( 16467123 )
2006
17
Estrogen receptor alpha-negative and progesterone receptor-positive breast cancer: lab error or real entity? ( 17189985 )
2006
18
Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer. ( 12408471 )
2002
19
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. ( 9196144 )
1997

Variations for Progesterone-Receptor Positive Breast Cancer

Expression for Progesterone-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Progesterone-Receptor Positive Breast Cancer.

Pathways for Progesterone-Receptor Positive Breast Cancer

Pathways related to Progesterone-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1 12.41 ERBB2 ESR1 ESR2
2
Show member pathways
12.22 ERBB2 ESR1 ESR2 PGR
3
Show member pathways
12.19 ERBB2 ESR1 ESR2
4
Show member pathways
12.1 ERBB2 ESR1 ESR2
5
Show member pathways
11.87 ERBB2 ESR1 ESR2
6
Show member pathways
11.53 ERBB2 ESR1 PGR
7 11.52 ESR1 ESR2
8
Show member pathways
11.49 ERBB2 ESR1
9
Show member pathways
11.29 ESR1 ESR2 PGR
10 10.9 ESR1 ESR2
11 10.85 ESR1 ESR2
12 10.77 ESR1 ESR2
13 10.64 CYP19A1 ESR2 PGR
14 9.4 CYP19A1 ESR1 ESR2

GO Terms for Progesterone-Receptor Positive Breast Cancer

Biological processes related to Progesterone-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA binding transcription factor activity GO:0051091 9.4 ESR1 ESR2
2 mammary gland development GO:0030879 9.37 CYP19A1 PGR
3 intracellular estrogen receptor signaling pathway GO:0030520 9.32 ESR1 ESR2
4 androgen metabolic process GO:0008209 9.26 CYP19A1 ESR1
5 uterus development GO:0060065 9.16 CYP19A1 ESR1
6 transcription initiation from RNA polymerase II promoter GO:0006367 9.13 ESR1 ESR2 PGR
7 steroid hormone mediated signaling pathway GO:0043401 8.8 ESR1 ESR2 PGR

Molecular functions related to Progesterone-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.71 ERBB2 ESR1 ESR2 PGR
2 sequence-specific DNA binding GO:0043565 9.69 ESR1 ESR2 PGR
3 enzyme binding GO:0019899 9.63 ESR1 ESR2 PGR
4 lipid binding GO:0008289 9.61 ESR1 ESR2 PGR
5 ATPase binding GO:0051117 9.49 ESR1 PGR
6 core promoter sequence-specific DNA binding GO:0001046 9.48 ESR1 ESR2
7 steroid hormone receptor activity GO:0003707 9.43 ESR1 ESR2 PGR
8 estrogen receptor activity GO:0030284 9.37 ESR1 ESR2
9 estrogen response element binding GO:0034056 9.32 ESR1 ESR2
10 RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding GO:0038052 9.16 ESR1 ESR2
11 nuclear receptor activity GO:0004879 9.13 ESR1 ESR2 PGR
12 steroid binding GO:0005496 8.8 ESR1 ESR2 PGR

Sources for Progesterone-Receptor Positive Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....